Lexicon Pharmaceuticals CEO Lonnel Coats, who departs July 7
Lexicon resubmits type 1 diabetes drug to FDA five years after rejection
Lexicon’s type 1 diabetes drug is finally getting another shot at the FDA.
The biotech announced Friday morning that it had …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
